greeksoup/ stock research
Stock research / United States / TEVA · Pharmaceutical Preparations · NYSE

Teva Pharmaceutical Industries Ltd. (TEVA)

Teva makes and sells generic medicines and a smaller range of branded ones, in neuroscience, immunology, respiratory and oncology. It was incorporated in Israel on 13 February 1944 and is the successor to a number of Israeli corporations, the oldest of which was established in 1901. It is headquartered in Israel and reports about 34,000 employees across 57 markets.

Teva Pharmaceutical Industries Ltd.

Teva makes and sells generic medicines and a smaller range of branded ones, in neuroscience, immunology, respiratory and oncology. It was incorporated in Israel on 13 February 1944 and is the successor to a number of Israeli corporations, the oldest of which was established in 1901. It is headquartered in Israel and reports about 34,000 employees across 57 markets.

Three regions

The business is run as three segments, United States, Europe and International Markets, and each one manages the whole product range in its own region rather than a single product line. International Markets covers everything outside the first two and reaches more than 35 countries, among them Canada and Israel on the regulated generic side and Russia and parts of Latin America where branded generics dominate. Alongside the three sit other activities: selling active pharmaceutical ingredients to other companies, contract manufacturing, and an out-licensing platform run through an affiliate called Medis. Roughly 43% of what the company took in during 2025 was denominated in currencies other than the US dollar, with the euro, the British pound and the Swiss franc among the main ones.

The generics side

In the United States the company markets more than 350 generic prescription products in more than 1,100 dosage strengths, packaging sizes and forms, covering oral solids, injectables, inhaled products, liquids, transdermal patches, ointments and creams. Most of those American generic sales go to retail drug chains, mail order distributors and wholesalers. Anda, its American distribution arm, carries generic, biosimilar and branded medicines and over-the-counter products, its own and other manufacturers', out to independent pharmacies, pharmacy chains, hospitals and physician offices. In Europe the over-the-counter range runs under SUDOCREM as a global brand alongside local ones such as NasenDuo, DICLOX FORTE, OLFEN Max and FLEGAMINA.

The branded medicines

The filing describes this half as the innovative portfolio, and it is concentrated in the central nervous system. AUSTEDO and AUSTEDO XR, for chorea in Huntington's disease and for tardive dyskinesia, sold $2,217 million in the United States in 2025, 35% more than in 2024. AJOVY, for preventing migraine, sold $295 million in the United States, $270 million in Europe and $108 million in International Markets, and the company reports its American exit market share at 33.3% of the subcutaneous injectable anti-CGRP class. UZEDY, for schizophrenia and bipolar 1 disorder in adults, sold $191 million in the United States, 63% more than in 2024. COPAXONE treats relapsing forms of multiple sclerosis, and the filing notes that alternative therapies to glatiramer acetate products have been introduced in various European markets. Oncology runs through TRUXIMA and BENDEKA, and the recently launched biosimilars are SELARSDI and EPYSQLI.

Making it

The company operates 33 finished dosage and packaging plants in 21 countries, turning out roughly 66 billion tablets and capsules and about 600 million sterile units in 2025. Most of that capacity sits in North America, Europe, Latin America, India and Israel, and external contract manufacturers are used alongside it. A separate estate of 13 production facilities makes about 350 active pharmaceutical ingredients, which are fed into its own plants and sold on. In recent years plants in the United States, Europe, Israel, Japan and India have been closed or sold as the manufacturing network was consolidated.

What is changing

The company announced a plan it calls Pivot to Growth in May 2023 and says 2025 was the year it entered that plan's Accelerate Growth phase. The company states that it intends to divest the active pharmaceutical ingredients business to concentrate on what it treats as its core. It divested its Teva-Takeda business venture in Japan on 31 March 2025, having held 51% of the venture, and stopped consolidating it from that date. On 7 May 2025 the company announced that its transformation programmes are expected to generate about $700 million of net savings through 2027.

From Teva's annual report on Form 10-K for the year ended 31 December 2025. The filing

Compare with another name What $10,000 in Teva Pharmaceutical Industries became

Latest results

Latest quarterQ3 FY2026ended 30 September 2026 · 10-Q filed 3 November 2026
Revenue
$4.4 billion
-1.9% on the year · +6.1% on the quarter
Q4 FY2024Q3 FY2026
Net income
$233 million
-46.2% on the year
Q4 FY2024Q3 FY2026
Diluted EPS
$0.20
-45.9% on the year
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

Read the Q3 FY2026 results →the 10-Q on EDGAR ↗
Last full yearFY2025ended 31 December 2025 · 10-K filed 3 February 2026
Revenue
$17.3 billion
+4.3% on the year
FY2018FY2025
Net income
$1.4 billion
FY2018FY2025
Diluted EPS
$1.21
FY2018FY2025

this yearthe year beforeHover a bar for its figure.

The years before, in wordsTeva Pharmaceutical Industries (TEVA) reported revenue of $17.3 billion for fiscal 2025, the year ended 31 December 2025, up 4.3% on the year before. Net income was $1.4 billion and diluted earnings per share $1.21. Revenue was $16.5 billion in fiscal 2024, $15.8 billion in fiscal 2023, $14.9 billion in fiscal 2022 and $15.9 billion in fiscal 2021. Net income in the same years was a loss of $1.6 billion, a loss of $559 million, a loss of $2.4 billion and $417 million. Over the twelve months to 30 September 2026, Teva Pharmaceutical Industries reported revenue of $17.2 billion and net income of $507 million. Revenue grew 0.7% a year, compounded, over the five years to fiscal 2025. Teva Pharmaceutical Industries had 1.17 billion shares outstanding at the latest filed count. At 30 September 2026 it carried $16.7 billion of debt and $4.1 billion of cash. At the close of 10 November 2026 the market cap of Teva Pharmaceutical Industries was $49.5 billion, 98.6 times its earnings over the last twelve months.
Read the FY2025 results →the 10-K on EDGAR ↗

Ratios

From the filings

ROE6.4%
ROCE5.8%
Operating margin8.3%
Net margin2.9%
FCF margin7.2%
Interest covern/a
Debt to equity2.10x
Cash conversion3.49x
Share count, last 12 months1.7%
Sales CAGR, 3 years5.0%
Profit CAGR, 3 yearsn/a
EPS, TTM$0.43

At the close of 10 November 2026

Price$42.40
Market cap$49.5 billion
Stock P/E98.6x
Price to book6.2x
EV / EBITDA25.7x
Dividend yieldn/a
Market cap / sales2.9x
52-week high$42.99
52-week low$24.21
Price, 1 year74.8%
Price CAGR, 3 years69.7%
Price CAGR, 5 years34.8%

29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →

Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on the borrowing lines of Teva Pharmaceutical Industries Ltd.'s balance sheet, added together, finance leases inside them only where the company puts them there; operating leases are a separate line. Nothing here is a valuation or a view.
TEVAgreeksoup.ai
Daily prices to 10 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.

Quarterly results

Q4 FY2021 *Q1 FY2022Q2 FY2022 †Q3 FY2022 †Q4 FY2022 *Q1 FY2023 †Q2 FY2023 †Q3 FY2023 †Q4 FY2023 * †Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue4,0993,6613,7863,5953,8833,6613,8783,8504,4573,8194,1644,3324,2293,8914,1764,4804,7113,9824,1424,395
Cost of revenue2,0501,9211,9921,9262,1132,0792,0821,9992,0402,0482,1402,1832,1102,0142,0742,1762,0562,0111,9891,955
Gross profit2,0491,7401,7941,6691,7701,5821,7961,8512,4161,7712,0242,1482,1211,8772,1022,3042,6551,9722,1532,440
Gross margin50%48%47%46%46%43%46%48%54%46%49%50%50%48%50%51%56%50%52%56%
R&D24354.02281758.0234240253226242269240247247244256266222970297
Operating income77.0-713-967424-940-13.0-654344756-218-5.0-51.0-29.0519455882301652-231714
Operating margin2%-19%-26%12%-24%-0%-17%9%17%-6%-0%-1%-1%13%11%20%6%16%-6%16%
Pre-tax income-176-971-1,178171-1,185-272-92364.0507-467-246-324-24729420364680.0437-455300
Tax raten/an/an/a63%n/an/an/a-19%8%n/an/an/an/a25%-38%33%-488%15%n/a22%
Net income-159-955-23256.0-1,301-220-87269.0464-139-846-437-217214282433481369-576233
Net margin-4%-26%-6%2%-34%-6%-22%2%10%-4%-20%-10%-5%5%7%10%10%9%-14%5%
Diluted EPS-$0.14-$0.86-$0.21$0.05-$1.17-$0.20-$0.78$0.06$0.41-$0.12-$0.75-$0.39-$0.19$0.18$0.24$0.37$0.41$0.31-$0.49$0.20
Operating cash flow456-49.0123543973-1453245.01,184-124103693575-1052273691,158-40.0411241
Capital expenditure15315712712214213911914911912497.014812912796.0136142168104120
Free cash flow303-206-4.0421831-284205-1441,065-2486.0545446-2321312331,016-208307121
Shares outstanding1,103m1,110m1,111m1,111m1,111m1,120m1,121m1,121m1,121m1,133m1,133m1,133m1,134m1,147m1,147m1,147m1,150m1,164m1,165m1,167m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Income statement (profit and loss)

FY2007FY2008FY2009 †FY2010 †FY2011 †FY2012FY2013FY2014 †FY2015 †FY2016 †FY2017 †FY2018 †FY2019 †FY2020 †FY2021 †FY2022 †FY2023FY2024FY2025TTM
Revenue9,40811,08513,89916,12118,31220,31720,31420,27219,65221,90321,85318,27116,88716,65915,87814,92515,84616,54417,25817,230
Cost of revenue4,5315,1176,5327,0568,7979,6659,6079,2168,29610,25011,2379,9759,3518,9338,2847,9528,2008,4818,3208,011
Gross profit4,8775,9687,3679,0659,51510,65210,70711,05611,35611,65310,6158,2967,5377,7267,5946,9737,6458,0648,9389,220
Gross margin51.8%53.8%53.0%56.2%52.0%52.4%52.7%54.5%57.8%53.2%48.6%45.4%44.6%46.4%47.8%46.7%48.2%48.7%51.8%53.5%
Research and development58178682595115.073.05.00.035.04221751141,01099796798.09539981,0131,755
Operating income2,3951,1452,4053,8713,1092,2051,6493,9513,3522,154-17,484-1,637-443-3,5721,716-2,197433-3032,1571,436
Operating margin25.5%10.3%17.3%24.0%17.0%10.9%8.1%19.5%17.1%9.8%-80.0%-9.0%-2.6%-21.4%10.8%-14.7%2.7%-1.8%12.5%8.3%
Interest expensen/a2012302022343553143002705468759208229018919301,0291,002916n/a
Pre-tax income2,3048002,2033,6462,9561,8191,2503,6382,352824-18,379-2,596-1,265-4,406658-3,163-624-1,2841,223362
Income tax386184166283127-137-43.0591634521-1,933-195-278-168211-643-7.0676-180-136
Effective tax rate16.8%23.0%7.5%7.8%4.3%-7.5%-3.4%16.2%27.0%63.2%n/an/an/an/a32.1%n/an/an/a-14.7%-37.6%
Net income1,9146092,0003,3312,7591,9631,2693,0551,588329-16,265-2,150-999-3,990417-2,446-559-1,6391,410507
Net margin20.3%5.5%14.4%20.7%15.1%9.7%6.2%15.1%8.1%1.5%-74.4%-11.8%-5.9%-24.0%2.6%-16.4%-3.5%-9.9%8.2%2.9%
Diluted EPS$2.36$0.75$2.23$3.67$3.09$2.25$1.49$3.56$1.82$0.07-$16.26-$2.35-$0.91-$3.64$0.38-$2.20-$0.50-$1.45$1.21$0.43
Filing20-F20-F20-F20-F20-F20-F20-F20-F20-F10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
From each year's filing, linked: the 10-K and the 20-F; TTM is the last four quarters.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Revenue by segment FY2015 to FY2025

FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
United Statesn/an/an/an/an/an/an/a7,0037,7318,0349,18653.2%
Europen/a4,9695,4665,1864,7954,7574,8864,5254,8375,1035,04029.2%
International Marketsn/a4,0152,8632,4222,2462,1542,0322,3522,3512,4632,16212.5%
Other Activitiesn/a1,1411,3831,3661,3041,3021,1511,0459269448705.0%
Generics10,540n/an/an/an/an/an/an/an/an/an/an/a
North American/a11,77812,1419,2978,5428,4477,809n/an/an/an/an/a
Specialty8,338n/an/an/an/an/an/an/an/an/an/an/a
Not assigned to a part in the filing774n/an/an/an/an/an/an/an/an/an/an/a
United States FY2022 to FY2025Europe FY2016 to FY2025International Markets FY2016 to FY2025Other Activities FY2016 to FY2025North America FY2016 to FY2021Generics FY2015Specialty FY2015
18.9FY201521.9FY201716.9FY201915.9FY202115.8FY202317.3FY2025

$ billion; hover a block for its figure and share; the figure over a bar is its parts, before the lines named below; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in. Not assigned to a part in the filing is the company's own eliminations and corporate items, which take the parts to revenue: shown as filed, with no share and no block in the chart.

Profit by segment FY2015

The operating profit each segment reports. Costs Teva Pharmaceutical Industries does not charge to a segment are left out, so the segments can add up to more than the company's own operating profit.

FY2015Margin
FY2015
Generics2,92527.8%
Specialty4,36152.3%
GenericsSpecialty
7,286FY2015

$ million; the figure over a bar is all the segments together. Hover a block for its profit, sales and margin.

FY2015Share of salesShare of profit
Generics56%40%
Specialty44%60%

Each column adds to 100%. A segment with a bigger share of the profit than of the sales makes more on each dollar it sells.

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where every segment with sales that year has an operating profit figure. A margin is a segment's operating profit over its own sales.

Revenue by product or service FY2015 to FY2025

FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
Sale of Goodsn/a19,98919,25615,88114,51014,35413,82912,76612,97914,05014,60584.6%
Distributionn/a9631,3841,3731,5141,4951,3901,5191,6151,5761,5519.0%
Licensing Arrangementsn/a3143271651471291602126811736783.9%
Othern/a6378868527166805004285707454232.5%
Branded8,338n/an/an/an/an/an/an/an/an/an/an/a
Generics10,540n/an/an/an/an/an/an/an/an/an/an/a
Other Products774n/an/an/an/an/an/an/an/an/an/an/a
Sale of Goods FY2016 to FY2025Distribution FY2016 to FY2025Licensing Arrangements FY2016 to FY2025Other FY2016 to FY2025Generics FY2015Branded FY2015Other Products FY2015
19.7FY201521.9FY201716.9FY201915.9FY202115.8FY202317.3FY2025

$ billion; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

Cash flow

FY2007FY2008FY2009 †FY2010 †FY2011 †FY2012FY2013FY2014 †FY2015 †FY2016 †FY2017 †FY2018 †FY2019 †FY2020 †FY2021 †FY2022 †FY2023FY2024FY2025TTM
Operating cash flow1,8133,2313,3734,1364,1344,5723,2375,1275,5423,8902,2252,4467481,2167981,5901,3681,2471,6491,770
Capital expenditure5426817197101,0531,1041,031929772901874651525578562548526498501534
Free cash flow1,2712,5502,6543,4263,0813,4682,2064,1984,7702,9891,3511,7952236382361,0428427491,1481,236
Free cash flow margin13.5%23.0%19.1%21.3%16.8%17.1%10.9%20.7%24.3%13.6%6.2%9.8%1.3%3.8%1.5%7.0%5.3%4.5%6.7%7.2%
Cash from investing-1,353-4,137-916-5,455-7,601-1,134-1,147-1,450-5,565-34,4053,4461,8661,3558631,523656968792737113
Cash from financing-3621,358-2,2655733,336-1,678-3,883-2,3754,80525,217-5,750-3,351-1,926-1,885-2,172-1,487-1,913-1,791-2,15158.0
Depreciation and amortisation4994909089771,0691,7081,6421,5081,3081,5242,1121,8421,7221,5571,3301,3081,1531,0591,002983
Share-based compensation67.063.054.080.091.082.064.095.0117124133155119129119124121123157172
Buybacks1520.00.099.08991,1614975004390.00.0n/an/an/an/an/an/an/an/an/a
Dividends paid2993875296688008551,0891,1561,1551,30390112.0n/an/an/an/an/an/an/an/a
Dividend per sharen/a$0.50$0.61$0.74$0.89$1.03$1.28$1.34$1.36$1.36$1.36$0.00$0.00n/an/an/an/an/an/an/a
Diluted shares, weighted830m820m896m921m893m873m850m858m864mn/a1,016m1,021m1,091m1,095m1,107m1,110m1,119m1,131m1,163m1,183m
Shares outstanding at period endn/a889m923m937mn/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a1,167m
Filing20-F20-F20-F20-F20-F20-F20-F20-F20-F10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
Cash paid in the year, from the cash flow statement.
Read moreThe dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet

FY2007FY2008FY2009 †FY2010 †FY2011 †FY2012FY2013FY2014 †FY2015 †FY2016 †FY2017 †FY2018 †FY2019 †FY2020 †FY2021 †FY2022 †FY2023FY2024FY2025TTM
Funded by
Shareholders' equity13,86416,37819,22221,94722,19522,76822,56523,31329,76933,33717,35914,70713,97210,02610,2787,8047,5065,3737,9107,979
Non-controlling interestn/a60.037.055.014899.071.042.01581,6561,3861,0871,0911,0359667946207.04.05.0
Redeemable equityn/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a0.03400.0n/a
Short-term borrowingsn/an/an/an/an/an/an/a46.075.0n/an/an/an/an/an/an/an/an/an/an/a
Debtn/a3,6544,0584,80011,39414,14311,2038,5668,35835,80032,47528,91626,90725,91923,04321,21219,83317,78316,80616,718
Operating lease liabilitiesn/an/an/an/an/an/an/an/an/an/an/an/a435479416349320296288266
Other liabilitiesn/a12,8289,89311,35016,40513,59913,66914,45315,89822,09719,39515,97315,06513,18112,96313,84715,20015,52715,74015,074
Total liabilities and equityn/a32,92033,21038,15250,14250,60947,50846,42054,25892,89070,61560,68357,47050,64047,66644,00643,47939,32640,74840,042
Owned
Fixed assetsn/a3,6993,7664,3575,9476,3156,6356,5356,5448,0737,6736,8686,4366,2965,9825,7395,7504,5814,0803,747
Goodwilln/a12,29712,67415,23218,29318,85618,98118,40819,02544,40928,41424,91724,84620,62417,63317,17717,17715,14716,00015,742
Intangible assetsn/a4,5814,0535,75110,3167,7456,4765,5127,67521,48717,64014,00511,2328,9237,4666,2705,3874,4183,7813,303
Investmentsn/a53.025336.0n/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Cash and equivalents1,4881,8541,9951,2481,0962,8791,0382,2266,9469889631,7821,9752,1772,1652,8013,2263,3003,5564,085
Receivablesn/a4,6535,0195,4766,2135,5725,3385,4085,3507,5237,1285,8225,6764,5814,5293,6963,4083,0593,7093,837
Inventoryn/a3,3963,3323,8665,0125,5025,0534,3713,9664,9544,9244,7314,4224,4033,8183,8334,0213,0073,1793,173
Other assetsn/a2,3872,1182,1863,2653,7403,9873,9604,7525,4563,8732,5582,8833,6366,0734,4904,5105,8146,4436,155
Total assetsn/a32,92033,21038,15250,14250,60947,50846,42054,25892,89070,61560,68357,47050,64047,66644,00643,47939,32640,74840,042
Filing20-F20-F20-F20-F20-F20-F20-F20-F20-F10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
At the fiscal year end; the TTM column is the latest quarter end.
Read moreBoth totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compounded-1.3%0.7%5.0%2.7%
Profit growth, compounded-1.2%n/an/a-28.8%
Return on equity, average-20.2%-9.5%-6.7%17.8%
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read moreReturn on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Questions

What was Teva Pharmaceutical Industries' revenue in fiscal 2025?

Teva Pharmaceutical Industries (TEVA) reported revenue of $17.3 billion for fiscal 2025, the year ended 31 December 2025, up 4.3% on the year before.

How much did Teva Pharmaceutical Industries earn in fiscal 2025?

Net income was $1.4 billion for fiscal 2025, and diluted earnings per share $1.21.

What is Teva Pharmaceutical Industries' P/E ratio?

At the close of 10 November 2026, Teva Pharmaceutical Industries traded at 98.6 times its earnings over the twelve months to 30 September 2026.

What is Teva Pharmaceutical Industries' market cap?

The market cap of Teva Pharmaceutical Industries was $49.5 billion at the close of 10 November 2026.

How much debt does Teva Pharmaceutical Industries have?

At 30 September 2026 Teva Pharmaceutical Industries carried $16.7 billion of debt and $4.1 billion of cash.

Peers: Pharmaceutical Products

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Eli Lilly & Co. LLY$1.35 trillion46.5168.5%n/a45.5%1.230.4%
Johnson & Johnson JNJ$675.9 billion42.5419.7%n/a7.8%0.551.9%
AbbVie Inc. ABBV$519.4 billion50.58n/a32.2%10.7%n/a2.4%
Merck & Co., Inc. MRK$364.8 billion152.575.5%n/a4.9%1.202.3%
Novartis AG NVS *$311.5 billion22.8330.3%n/a8.4%0.622.5%
AstraZeneca PLC AZN *$289.7 billion28.5621.0%23.4%8.6%0.571.7%
Abbott Laboratories ABT$191.3 billion41.219.2%13.8%10.0%0.612.3%
Novo Nordisk A/S NVO *$181.7 billion11.8452.8%41.3%6.4%0.674.3%
Pfizer Inc. PFE$167.3 billion41.944.5%n/a1.3%0.705.9%
Vertex Pharmaceuticals Inc. VRTX$138.9 billion35.2419.0%33.2%10.5%0.22n/a
Bristol-Myers Squibb Co. BMY$128.4 billion13.9239.5%22.6%4.2%1.834.0%
Sanofi SNY *$117.6 billion13.5710.9%n/a6.2%0.264.6%
All 174 in Pharmaceutical Products
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Eli Lilly & Co. LLY$1.35 trillion46.5168.5%n/a45.5%1.230.4%
Johnson & Johnson JNJ$675.9 billion42.5419.7%n/a7.8%0.551.9%
AbbVie Inc. ABBV$519.4 billion50.58n/a32.2%10.7%n/a2.4%
Merck & Co., Inc. MRK$364.8 billion152.575.5%n/a4.9%1.202.3%
Novartis AG NVS *$311.5 billion22.8330.3%n/a8.4%0.622.5%
AstraZeneca PLC AZN *$289.7 billion28.5621.0%23.4%8.6%0.571.7%
Amgen Inc. AMGN$251.6 billion26.9865.4%32.4%8.2%3.762.2%
Gilead Sciences, Inc. GILD$212.1 billionn/a-29.6%-7.6%6.5%2.011.9%
Abbott Laboratories ABT$191.3 billion41.219.2%13.8%10.0%0.612.3%
Novo Nordisk A/S NVO *$181.7 billion11.8452.8%41.3%6.4%0.674.3%
Pfizer Inc. PFE$167.3 billion41.944.5%n/a1.3%0.705.9%
Vertex Pharmaceuticals Inc. VRTX$138.9 billion35.2419.0%33.2%10.5%0.22n/a
Bristol-Myers Squibb Co. BMY$128.4 billion13.9239.5%22.6%4.2%1.834.0%
Sanofi SNY *$117.6 billion13.5710.9%n/a6.2%0.264.6%
GSK plc GSK *$102.8 billion13.8034.9%24.3%4.1%1.083.3%
Moderna, Inc. MRNA$101.3 billionn/a-40.8%-116.0%13.1%0.52n/a
Regeneron Pharmaceuticals, Inc. REGN$96.8 billion20.2314.4%28.8%18.6%0.060.4%
Takeda Pharmaceutical Company Limited TAK *$66.1 billionn/a-2.1%0.1%-1.7%0.663.1%
argenx SE ARGX *$60.1 billion49.6617.6%n/a89.9%0.00n/a
IDEXX Laboratories Inc. IDXX$54.9 billion46.9563.2%32.3%11.9%0.45n/a
Teva Pharmaceutical Industries Ltd. TEVA$49.5 billion98.596.4%8.3%2.7%2.10n/a
Royalty Pharma plc RPRX$38.7 billion45.696.9%57.1%11.4%0.881.3%
Biogen Inc. BIIB$37.4 billion108.211.8%4.3%2.3%0.41n/a
Genmab A/S GMAB *$34.7 billion35.1916.5%28.6%19.2%0.90n/a
Zoetis Inc. ZTS$33.6 billion14.0275.3%n/a1.0%2.742.5%
Roivant Sciences Ltd. ROIV$29.8 billionn/a-8.6%-1,358.1%102.1%0.00n/a
Insmed Inc. INSM$26.2 billionn/a-83.4%-37.1%240.0%0.76n/a
United Therapeutics Corp. UTHR$24.9 billion22.1919.6%41.4%1.9%0.00n/a
Viatris Inc. VTRS$23.9 billionn/a-4.4%-0.0%4.3%0.972.3%
BioNTech SE BNTX *$21.9 billionn/a-5.9%-49.0%4.3%0.01n/a
Alnylam Pharmaceuticals, Inc. ALNY$20.3 billion7.8775.6%19.5%56.2%0.28n/a
Exelixis, Inc. EXEL$17.3 billion21.1248.3%40.2%9.1%0.00n/a
Neurocrine Biosciences Inc. NBIX$17.1 billion25.0918.1%24.0%38.0%0.00n/a
Jazz Pharmaceuticals plc JAZZ$15.8 billion83.524.9%9.0%13.5%1.33n/a
BridgeBio Pharma, Inc. BBIO$15.4 billionn/an/a-38.5%167.3%n/an/a
Kiniksa Pharmaceuticals International, plc KNSA$14.9 billion73.1415.4%13.8%58.2%0.00n/a
Elanco Animal Health Inc. ELAN$13.4 billionn/a-2.2%n/a12.1%0.52n/a
Dr. Reddy’s Laboratories Limited RDY *$12.4 billion27.1511.4%15.0%3.2%0.210.6%
Halozyme Therapeutics, Inc. HALO$11.7 billion26.22n/a37.4%45.0%n/an/a
Kymera Therapeutics, Inc. KYMR$11.7 billionn/a-21.6%-396.0%133.8%0.00n/a
Bio-Techne Corp. TECH$11.4 billion66.817.9%19.6%0.9%0.090.4%
Biomarin Pharmaceutical Inc. BMRN$11.1 billionn/a-0.3%3.1%18.1%0.67n/a
Madrigal Pharmaceuticals, Inc. MDGL$10.0 billionn/a-24.8%-10.7%92.8%0.54n/a
Repligen Corp. RGEN$9.9 billionn/a-0.6%2.3%13.8%0.27n/a
TG Therapeutics, Inc. TGTX$9.7 billion97.3918.5%21.5%68.8%1.30n/a
Krystal Biotech, Inc. KRYS$9.1 billion41.6015.7%48.4%26.0%0.00n/a
Protagonist Therapeutics, Inc. PTGX$8.9 billion28.8531.5%58.6%163.7%0.00n/a
Twist Bioscience Corp. TWST$8.3 billionn/a-30.7%-33.6%19.2%0.03n/a
Corcept Therapeutics Inc. CORT$8.0 billion57.7619.5%11.5%30.0%0.00n/a
Rhythm Pharmaceuticals, Inc. RYTM$7.9 billionn/a-220.3%-66.7%61.0%1.17n/a
Cytokinetics Inc. CYTK$7.8 billionn/an/a-625.2%29.9%n/an/a
Alkermes plc. ALKS$7.8 billionn/a-0.0%3.7%15.3%0.81n/a
Amneal Pharmaceuticals, Inc. AMRX$7.5 billion50.9325.1%15.0%8.9%5.87n/a
Axsome Therapeutics, Inc. AXSM$7.4 billionn/a-149.2%-17.5%54.2%1.78n/a
ImmunityBio, Inc. IBRX$7.2 billionn/an/a-150.2%121.2%n/an/a
Arrowhead Pharmaceuticals, Inc. ARWR$6.9 billionn/a-68.7%-33.8%16.8%1.86n/a
Lantheus Holdings, Inc. LNTH$6.6 billion25.0319.9%18.6%2.4%0.42n/a
CG Oncology, Inc. CGON$6.5 billionn/a-24.0%-4,293.5%183.6%0.00n/a
Ligand Pharmaceuticals Inc. LGND$6.3 billion140.125.4%9.5%1.0%1.17n/a
Mirum Pharmaceuticals, Inc. MIRM$6.2 billionn/an/a-133.6%42.2%n/an/a
Scholar Rock Holding Corp. SRRK$5.9 billionn/an/an/an/a1.16n/a
PTC Therapeutics, Inc. PTCT$5.4 billionn/an/a12.8%-35.1%n/an/a
Travere Therapeutics, Inc. TVTX$5.0 billionn/a-538.0%-20.5%49.4%26.72n/a
Adaptive Biotechnologies Corp. ADPT$4.7 billionn/a-40.0%-16.2%17.9%1.90n/a
Ionis Pharmaceuticals Inc. IONS$4.7 billionn/a-138.8%-58.8%-0.7%3.36n/a
Liquidia Corp. LQDA$4.6 billionn/an/a-15.6%798.4%n/an/a
Relay Therapeutics, Inc. RLAY$4.4 billionn/a-35.9%-3,094.9%23.9%0.00n/a
Crispr Therapeutics AG CRSP$4.4 billionn/a-27.7%-2,114.8%-34.3%0.36n/a
Tango Therapeutics, Inc. TNGX$4.1 billionn/a-21.2%n/an/a0.00n/a
AbCellera Biologics Inc. ABCL$4.1 billionn/a-14.0%-298.0%92.1%0.00n/a
Xenon Pharmaceuticals Inc. XENE$4.1 billionn/a-37.4%n/an/a0.00n/a
Iovance Biotherapeutics, Inc. IOVA$3.7 billionn/a-27.1%-60.8%51.3%0.00n/a
Viking Therapeutics, Inc. VKTX$3.7 billionn/a-106.6%n/an/a0.43n/a
Organon & Co. OGN$3.6 billion18.2717.9%n/a-3.2%7.170.6%
Tarsus Pharmaceuticals, Inc. TARS$3.6 billionn/a-675.0%-102.0%86.3%0.700.0%
DBV Technologies S.A. DBVT$3.6 billionn/a-139.5%-5,420.1%-31.5%0.00n/a
Viridian Therapeutics, Inc. VRDN$3.5 billionn/a-78.1%-1,781.4%-62.8%0.63n/a
Arcutis Biotherapeutics, Inc. ARQT$3.5 billion130.5712.3%6.9%60.0%0.45n/a
Supernus, Inc. SUPN$3.4 billion8.03n/a40.6%16.4%n/an/a
Denali Therapeutics Inc. DNLI$3.2 billionn/an/an/an/a0.00n/a
Acadia Pharmaceuticals Inc. ACAD$3.2 billion8.6626.1%10.2%14.8%0.00n/a
Bausch Health Companies Inc. BHC$3.1 billionn/an/a11.2%10.8%n/an/a
Ideaya Biosciences, Inc. IDYA$3.1 billionn/an/an/an/a0.00n/a
Vericel Corp. VCEL$3.0 billion92.278.7%8.3%25.3%0.00n/a
Xencor Inc. XNCR$2.9 billionn/a-21.0%-72.7%33.5%0.17n/a
Xeris Biopharma Holdings, Inc. XERS$2.9 billionn/a-13.3%12.7%38.4%3.89n/a
Adma Biologics, Inc. ADMA$2.8 billion16.4441.6%46.5%6.3%0.45n/a
Silence Therapeutics plc SLN$2.8 billionn/a-155.8%-11,106.8%-97.7%0.00n/a
Beam Therapeutics Inc. BEAM$2.6 billionn/a-11.2%-267.7%163.3%0.11n/a
Neogen Corp. NEOG$2.5 billionn/a-2.7%-0.8%-0.3%0.37n/a
Septerna, Inc. SEPN$2.5 billionn/a-13.8%-76.2%336.7%0.00n/a
Schrodinger, Inc. SDGR$2.4 billionn/a-19.6%-49.6%4.8%0.00n/a
Celldex Therapeutics, Inc. CLDX$2.4 billionn/a-47.6%-213,033.8%-94.0%0.00n/a
Arcus Biosciences, Inc. RCUS$2.4 billionn/a-126.5%-475.0%-58.3%0.28n/a
Perrigo Co. plc PRGO$2.3 billionn/a-72.5%-39.4%-4.5%1.356.9%
NewAmsterdam Pharma Co. N.V. NAMS$2.3 billionn/a-32.5%-900.1%-26.4%0.00n/a
Zymeworks Inc. ZYME$2.2 billion60.5016.8%16.6%97.8%1.31n/a
Vir Biotechnology, Inc. VIR$2.2 billionn/a-20.6%-69.8%1,696.0%0.00n/a
Aurinia Pharmaceuticals Inc. AUPH$2.2 billion7.1247.8%48.6%21.0%0.00n/a
Prestige Consumer Healthcare Inc. PBH$2.1 billion13.898.0%25.0%5.1%1.07n/a
Immunome Inc. IMNM$2.1 billionn/a-62.2%n/an/a0.00n/a
Maze Therapeutics, Inc. MAZE$2.0 billionn/an/an/an/a0.09n/a
Recursion Pharmaceuticals, Inc. RXRX$2.0 billionn/a-52.5%-725.4%56.2%0.01n/a
Harmony Biosciences Holdings, Inc. HRMY$2.0 billion11.1116.7%22.2%19.8%0.14n/a
Eton Pharmaceuticals, Inc. ETON$1.9 billion44.3657.4%28.8%100.6%0.27n/a
Zenas BioPharma, Inc. ZBIO$1.9 billionn/an/an/an/a1.41n/a
Biocryst Pharmaceuticals Inc. BCRX$1.9 billionn/an/a-30.1%60.3%n/an/a
Agios Pharmaceuticals, Inc. AGIO$1.9 billionn/a-38.1%-297.7%214.4%0.00n/a
Trulieve Cannabis Corp. TRLV$1.9 billionn/a-57.8%-25.6%-9.1%0.37n/a
Generate Biomedicines, Inc. GENB$1.8 billionn/an/an/an/a0.00n/a
Stoke Therapeutics, Inc. STOK$1.8 billionn/a-69.0%-913.1%-86.3%0.00n/a
Sarepta Therapeutics, Inc. SRPT$1.8 billionn/a-7.5%-2.5%-18.9%0.56n/a
Nurix Therapeutics, Inc. NRIX$1.7 billion6.8730.5%41.3%738.8%0.000.0%
Novavax Inc. NVAX$1.7 billionn/an/a-21.2%-61.3%n/an/a
Immunocore Holdings plc IMCR$1.7 billionn/a-7.7%-6.8%13.1%0.940.0%
Ultragenyx Pharmaceutical Inc. RARE$1.6 billionn/an/a-64.0%15.8%n/an/a
Precigen, Inc. PGEN$1.6 billion129.2029.1%21.4%n/a1.12n/a
ANI Pharmaceuticals Inc. ANIP$1.6 billion14.0318.3%16.0%25.9%0.95n/a
uniQure N.V. QURE$1.6 billionn/a-79.0%-1,001.7%28.0%0.17n/a
Intellia Therapeutics, Inc. NTLA$1.6 billionn/a-69.5%-821.2%-8.1%0.12n/a
Nuvation Bio Inc. NUVB$1.5 billionn/a-59.6%-61.2%654.2%1.25n/a
Pacira BioSciences, Inc. PCRX$1.5 billion39.235.3%4.8%3.7%0.41n/a
Ocular Therapeutix, Inc. OCUL$1.5 billionn/a-74.1%-680.9%-9.7%0.17n/a
Phibro Animal Health Corp. PAHC$1.4 billion13.8524.6%12.5%10.1%1.761.4%
Korsana Biosciences, Inc. KRSA$1.4 billionn/an/an/an/a0.00n/a
Taysha Gene Therapies, Inc. TSHA$1.4 billionn/a-38.6%-2,792.3%-32.3%0.13n/a
Avalyn Pharma Inc. AVLN$1.4 billionn/an/an/an/a0.04n/a
Innoviva, Inc. INVA$1.4 billion9.5917.0%38.8%12.8%0.23n/a
Mannkind Corp. MNKD$1.4 billionn/an/a-2.9%31.7%n/an/a
Inhibrx Biosciences, Inc. INBX$1.3 billionn/an/an/an/an/an/a
Opko Health, Inc. OPK$1.3 billionn/a-13.3%-25.5%-21.9%0.43n/a
Cronos Group Inc. CRON$1.3 billion20.065.4%3.4%55.8%0.00n/a
Rapport Therapeutics, Inc. RAPP$1.2 billionn/an/an/an/a0.00n/a
Omeros Corp. OMER$1.2 billionn/an/an/an/an/an/a
UroGen Pharma Ltd. URGN$1.2 billionn/an/a-12.4%159.3%n/an/a
Amphastar Pharmaceuticals, Inc. AMPH$1.2 billion13.2812.1%18.7%3.1%0.75n/a
Harrow, Inc. HROW$1.1 billionn/a-97.6%-2.0%21.3%10.03n/a
Cryoport, Inc. CYRX$1.1 billionn/a-7.8%-20.0%1.1%0.39n/a
Odyssey Therapeutics, Inc. ODTX$957 millionn/an/an/an/a0.00n/a
Aktis Oncology, Inc. AKTS$934 millionn/an/an/an/a0.00n/a
MeiraGTx Holdings plc MGTX$906 million13.5436.6%46.3%948.3%0.46n/a
Monte Rosa Therapeutics, Inc. GLUE$896 millionn/a-26.4%-214.5%-61.3%0.00n/a
Syndax Pharmaceuticals Inc. SNDX$851 millionn/an/a-61.7%159.5%n/an/a
Lexicon Pharmaceuticals, Inc. LXRX$838 millionn/a-38.1%-147.4%-45.6%0.32n/a
Rigel Pharmaceuticals Inc. RIGL$827 million2.8369.0%26.3%2.2%0.02n/a
Verastem, Inc. VSTM$824 millionn/an/an/an/a11.82n/a
Ironwood Pharmaceuticals Inc. IRWD$797 million5.35n/a62.9%18.1%n/an/a
QuidelOrtho Corp. QDEL$791 millionn/a-20.6%-4.9%-4.5%1.64n/a
Ginkgo Bioworks Holdings, Inc. DNA$775 millionn/a-63.9%-242.5%-44.2%0.00n/a
Nektar Therapeutics NKTR$770 millionn/a-17.4%-257.8%-27.2%0.00n/a
Arbutus Biopharma Corp. ABUS$762 million3.38256.5%81.1%1,142.6%0.00n/a
Collegium Pharmaceutical, Inc. COLL$760 million24.4612.9%15.2%7.7%3.65n/a
Ardelyx, Inc. ARDX$754 millionn/a-33.8%-7.7%17.6%1.54n/a
Janux Therapeutics, Inc. JANX$736 millionn/a-11.0%-599.3%132.9%0.00n/a
Zevra Therapeutics, Inc. ZVRA$709 million9.8632.7%60.8%75.1%0.00n/a
Kura Oncology, Inc. KURA$695 millionn/a-1,630.7%-394.3%n/a0.55n/a
Design Therapeutics, Inc. DSGN$679 millionn/a-36.6%n/an/a0.00n/a
Wave Life Sciences, Inc. WVE$671 millionn/a-52.4%-320.9%n/a0.00n/a
Geron Corp. GERN$627 millionn/an/an/an/a0.53n/a
Aclaris Therapeutics, Inc. ACRS$626 millionn/a-47.7%-1,414.0%-59.3%0.00n/a
Myriad Genetics Inc. MYGN$541 millionn/a-48.0%-14.3%-2.6%0.45n/a
Monopar Therapeutics MNPR$481 millionn/an/an/an/a0.00n/a
Arvinas, Inc. ARVN$452 millionn/a-1.8%-12.1%-11.8%0.00n/a
Gyre Therapeutics, Inc. GYRE$452 millionn/a-37.5%-20.6%13.5%0.00n/a
Evolus, Inc. EOLS$450 millionn/an/a-4.8%13.9%n/an/a
Phathom Pharmaceuticals, Inc. PHAT$442 millionn/an/a-9.3%86.8%n/an/a
Aquestive Therapeutics, Inc. AQST$442 millionn/an/a-114.1%12.5%n/an/a
CytomX Therapeutics, Inc. CTMX$434 millionn/a-30.0%-676.5%-87.7%0.00n/a
Puma Biotechnology, Inc. PBYI$420 million17.6516.3%11.3%9.4%0.00n/a
CorMedix Inc. CRMD$416 million2.5040.6%47.0%n/a0.00n/a
Crescent Biopharma, Inc. CBIO$386 millionn/an/an/an/a0.00n/a
Canopy Growth Corp. CGC$251 millionn/an/a-54.2%10.7%0.38n/a
Atrium Therapeutics, Inc. RNA$141 millionn/an/an/an/an/an/a
Gossamer Bio, Inc. GOSS$69 millionn/an/a-140.0%78.0%n/an/a
124 companies share its SEC industry code (Pharmaceutical Preparations); the rest are the names nearest in size in its wider industry, Pharmaceutical Products, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

The public record on TEVA

Dividends$12.0 million paid in cash dividends in FY2018
Filings21 in twelve months: 13 current reports (8-K), about 5 results of operations; 3 other events; 2 material agreement; 2 new financial obligation; 2 regulation FD disclosure
Planned insider sales42 Form 144 notices in twelve months, $109.1 million; latest 10 November 2026
Options tapeput/call 0.47 by open interest at the 10 November 2026 close; the straddle prices a 3.4% move to 13 November 2026
13F holders679 funds reported a position for the quarter to 30 June 2026; largest BlackRock, Inc.
Insider trading59 sales and 0 purchases on Form 4 in twelve months
Congress0 House trades disclosed in six months
Short interest27.7 million shares short, 5.30 days to cover at 30 October 2026
Documentsthe 10-K, the 10-Qs, the proxy and 5 earnings press releases, each linked

Filings

FilingPeriodFiledWhere
10-Q30 September 20263 November 2026EDGAR
10-Q30 June 202629 July 2026EDGAR
10-Q31 March 202629 April 2026EDGAR
10-K31 December 20253 February 2026EDGAR
10-Q30 September 20255 November 2025EDGAR
10-Q30 June 202530 July 2025EDGAR
10-Q31 March 20257 May 2025EDGAR
10-K31 December 20245 February 2025EDGAR
10-Q30 September 20246 November 2024EDGAR
10-Q30 June 202431 July 2024EDGAR

Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.